Founded by Eclipse Ventures and Mayo Clinic, Nucleus RadioPharma is a new company built to ensure cancer patients can access potentially life-saving radiopharmaceuticals by developing technologies to modernize the clinical development, manufacturing, and supply chain of these promising new treatment tools.
Justin is a Partner at Eclipse, where he collaborates with founders working at the intersection of multiple disciplines. He is particularly passionate about novel approaches to complex issues in infrastructure in healthcare and life sciences.
Justin works with companies building technologies, products, and services that enable the development and, ultimately, the foundation upon which the next generation of healthcare and life sciences advancements can thrive. His focus is on building the infrastructure of these industries, closing the gap between scientific development and clinical deployment.
Prior to joining Eclipse, Justin built and led the commercial operations at Misfit, a digital health company acquired by the Fossil Group for more than $250M. Before Misfit, Justin managed the commercialization efforts in the foods, fuels, and chemicals spaces at Synthetic Genomics (SGI), a leading synthetic biology company.
Justin received his B.S. in Chemical Engineering from UCSB and his MBA from MIT Sloan. He sits on the Industry Alliance Board of the California Institute for Regenerative Medicine (CIRM) and the Commercial Advisory Board of the National Science Foundation Center for Cell Manufacturing Technology (CMat).
Justin enjoys skiing, mountain biking, and sailing and leads the Kathryn Butler Foundation in honor of his late wife, where he is working to support the needs of those battling cancer and bereaved children.
Geoffrey B Johnson, M.D., Ph.D. is the chair of Division of Nuclear Medicine in the Department of Radiology at the Mayo Clinic in Rochester, serving since 2016. During his tenure, the Nuclear Medicine practice has undergone transformative growth, ushering in new diagnostic and therapeutic technologies, and reimagining the multidisciplinary radiopharmaceutical theranostics practice. Dr. Johnson also serves the Mayo Clinic Comprehensive Cancer Center (MCCCC) as the associate medical director for radiology and radiopharmaceutical trials, and has previously served on the MCCCC solid tumor Study Review Committee (SRC). He serves as the medical director of the Molecular Imaging Resource core lab and as the director of the Molecular Imaging Research Program. Dr. Johnson has previously served as chair of PET/MR R&D, as medical director of the Nuclear Medicine Technologist Program and as director of the Nuclear Radiology Fellowship.
Dr. Johnson is board certified by the American Board of Nuclear Medicine (ABNM) and the American Board of Radiology (ABR) and is active in clinical practice in Nuclear Medicine and Thoracic Radiology. He has a joint research appointment in the Department of Immunology. Dr. Johnson earned his B.S. in chemical engineering from the Massachusetts Institute of Technology, receiving Tau Beta Phi academic honors. He completed his M.D./Ph.D. in the Mayo Medical-Scientist Training Program, with graduate training in Immunology. He went on to complete an internship in internal medicine, a residency in diagnostic radiology and a fellowship in nuclear radiology in Mayo School of Graduate Medical Education.
Dr. Johnson’s research interests include developing radiopharmaceuticals for imaging (PET and SPECT) and therapy of cancer and inflammatory diseases. His research funding includes the NIH and industry, and he is actively serving as the principal investigator on imaging and theranostic trials.
Manu S. Nair is Chair, Corporate Development in the Department of Business Development at Mayo Clinic. Mr. Nair leads the business development efforts focusing on US clinical practice and high-value opportunities that are of highest strategic importance to Mayo Clinic.
Prior to assuming this role, Mr. Nair served as vice president of Technology Ventures for the Oklahoma Medical Research Foundation (OMRF) in Oklahoma City. He oversaw developing and commercializing OMRF’s technologies, establishing strategic industry collaborations, and managing the innovation fund dedicated to such development efforts.
Mr. Nair started his technology commercialization career at OMRF in 2004 and was involved in OMRF’s intellectual property (IP) commercialization and startup company efforts. He later joined Mayo Clinic Ventures (MCV), the technology commercialization and investment arm of Mayo Clinic, where he served as a technology licensing manager and subsequently as senior licensing manager. He managed a diverse portfolio of technologies and was in charge of related IP protection, development and commercialization, including company formation and technology-based investments. He also led MCV’s international collaboration and funding initiatives.
Appointed by the governor of Oklahoma, Mr. Nair served as vice chair of the Oklahoma Science and Technology R&D Board. He has served on the Board of Directors of the Legal Assistance of Olmsted County, Rochester, Minnesota and the Midwest University Research Network. He currently serves on the boards of Jupiter Bioventures, Nucleus Radiopharma, vMocion and the USA Healthcare Alliance, serves on the business advisory board of Progentec Diagnostics, and is a member of the External Advisory Committee for the NIH-funded SE XLerator Network Hub. In addition, Mr. Nair serves as a business consultant for several U.S. and international entities, including prominent research institutes and technology companies.
Mr. Nair received his MBA from Lamar University in Texas and an advanced degree in law from the University of New Hampshire School of Law focusing on intellectual property, commerce and technology laws.
Michael Rossi is currently Medical Group President for Mirion Technologies. Michael served as the Head of Radioligand Imaging for the Advanced Accelerator Applications, a Novartis Company.
Michael also spent five years at Jubilant Pharma where he served in several different roles including President of Jubilant Radiopharma, and brings experience from GE Healthcare, Tyco Healthcare/Mallinckrodt and Syncor International.
Michael earned a Bachelor of Science in Pharmacy from the University of the Sciences, Philadelphia College of Pharmacy and holds an Authorized Nuclear Pharmacist Certification from Butler University. He has served on several Boards of Directors and remains a Licensed Pharmacist in the state of Pennsylvania.
Dr. Norman E. “Ned” Sharpless is a physician, scientist, entrepreneur, and former federal official. He served as Director of the National Cancer Institute from 2017 to 2022, and as Acting Commissioner of the US Food and Drug Administration in 2019.
Prior to government, Dr. Sharpless was Director of the Lineberger Comprehensive Cancer Center at UNC. He founded G1 Therapeutics, which developed the FDA-approved medicine Cosela (Trilaciclib), used to prevent chemotherapy toxicity.
He is a member of the American Association for Cancer Research Academy, the Association of American Physicians, and the American Society for Clinical Investigation.
Mary Kate Wold has held leadership positions in the pharmaceutical and healthcare, financial services, legal, and government sectors, including sitting on the boards of numerous organizations. She is the CEO and a board member of the Church Pension Group (CPG), a pension and financial services company that is headquartered in New York City.
Prior to joining CPG, Ms. Wold was Senior Vice President, Finance, and a Principal Corporate Officer of Wyeth, one of the world’s largest research-based pharmaceutical companies, leading its Treasury, Tax, Procurement, Enterprise Risk Management, and Business Process Outsourcing functions. Sitting on several executive oversight committees, she provided direction across a spectrum of Wyeth’s business and finance operations.
Before Wyeth, Ms. Wold was a partner and chaired the tax practice group of Shearman & Sterling, one of the world’s leading law firms. She advised the firm’s global clients on cross-border mergers and acquisitions and capital markets transactions. Earlier in her career, she served in the United States Department of the Treasury as a member of the Office of International Tax Counsel, where she negotiated the first income tax treaty between the United States and China.
Ms. Wold has served on numerous boards of both for-profit and non-profit organizations. She currently is a board member, sits on the executive and audit committees, and chairs the investment committee of The Jackson Laboratory, a biomedical research institution dedicated to the discovery of genomic solutions to cancer and other human diseases. She is a board member of the Burke Neurological Institute, a research organization affiliated with Weill Cornell Medicine, and is a member of its executive committee.
A native of North Dakota, Ms. Wold attended Hamline University in St. Paul, Minnesota, from which she graduated summa cum laude and was elected a member of Phi Beta Kappa. She graduated cum laude from the University of Michigan Law School. She holds an honorary degree of Doctor of Humane Letters from the Berkeley Divinity School at Yale University.
Charles S. Conroy brings to Nucleus more than 30 years of experience in the life sciences industry, including several significant senior positions within the radiopharmaceutical industry.
Most recently Mr. Conroy was the CEO of ARTMS, a revolutionary developer of isotope manufacturing equipment. Prior to joining ARTMS, he was the General Manager of Jubilant Pharma where he was responsible for North American sales and operations and has held leadership roles in various life sciences companies including Express Scripts, United BioSource Corporation, Covidien and Eli Lilly.
Kevin Haehl joins Nucleus after three decades in the pharmaceutical industry, most recently serving as the project leader and Site Head for Novartis’ newest radiopharmaceutical manufacturing plant in Indianapolis, Indiana. He also managed the CDMO supply chain network for Endocyte’s phase III trial for 177Lu-PSMA-617.
Kevin received his BS in Chemical Engineering from Purdue University and is licensed as a Professional Engineer. After a 20-year career with Eli Lilly and Company gaining experience in research, finance, manufacturing, and quality, he served in key leadership roles for the CDMOs Evonik and Unither Pharmaceuticals.